Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: The complementary role of PSMA expression and [18F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology

Fig. 2

Clinical examples of immunostaining and [18F]FDG PET/CT in two patients. In a, b images of a 71 year-old female patient affected by mixed papillary and follicular thyroid cancer (pT3pN0pM1, margins focally involved). She was classified at high risk of recurrence according to ATA Guidelines. PSMA immunostaining was scored as positive (a, 40% expression) and she had multiple [18F]FDG-avid bone and lung metastases (b). Disease recurrence occurred six months after treatment. At 16 months patient developed RAI-R, and she had persistent lung and bone disease at last follow-up visit at 38 months (thyroglobulin at last follow-up was 2043 ng/mL). In c–d–e images of a 60 year-old male patient with left papillary thyroid cancer (pT1pN1, margins involved). He was classified at high risk of structural disease recurrence according to ATA Guidelines. He had negative PSMA immunostaining (c). Thyroglobulin at the time of PET/CT was 40 ng/mL and even if imaging (d) did not show any abnormal [18F]FDG uptake, neck disease recurrence was confirmed few days after by Iodine-131 whole-body scan (e). At 23 months the patient developed RAI-R, and he had persistent nodal disease at last follow-up visit at 92 months (thyroglobulin of 5.2 ng/mL at last follow-up)

Back to article page